All In Biotech

Drug Trial Radar · NCT00202605

Safety and Efficacy of SPD465 in Adults With ADHD

A Phase II, Randomized, Double-Blind, Multi-center, Placebo-controlled, Crossover Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

Last checked: Nov 19, 2026Latest source record: Jun 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Sep 29, 2005

Primary completion

Jan 6, 2006

Study completion Jan 6, 2006

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Sep 20, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate how safe and how well SPD465 works compared to placebo in adults with ADHD. It is hypothesized that SPD465 will achieve an extended duration of clinical benefit.

Conditions

  • Attention Deficit Disorder With Hyperactivity

Interventions

  • Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d,I-amphetamine aspartate monohydrateDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PERMP (Permanent Product Measure of Performance)Time frame: 0.5 hours pre-dosing
  2. PERMP (Permanent Product Measure of Performance)Time frame: 2 hours post-dosing
  3. PERMP (Permanent Product Measure of Performance)Time frame: 4 hours post-dosing
  4. PERMP (Permanent Product Measure of Performance)Time frame: 8 hours post-dosing
  5. PERMP (Permanent Product Measure of Performance)Time frame: 12 hours post-dosing
  6. PERMP (Permanent Product Measure of Performance)Time frame: 14 hours post-dosing
  7. PERMP (Permanent Product Measure of Performance)Time frame: 16 hours post-dosing

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Study Center

    Little Rock, Arkansas

  • UCI Child Development Center

    Irvine, California

  • Center for Psychiatry and Behavioral Medicine, Inc.

    Las Vegas, Nevada

  • Bayou City Research, Ltd.

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.